Fampridine for SCA27B ataxia study
Part of Brain & nervous system, Eyes & vision clinical trials.
This trial tests if fampridine, a medication, can improve walking and coordination in people with SCA27B, a specific inherited ataxia. It compares fampridine to a placebo over a period of time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a genetic diagnosis of SCA27B with at least 250 GAA repeats in the FGF14 gene.
- You must be 18 years old or older.
- You must have trouble walking and other ataxia symptoms that are not too mild (SARA gait score of at least 1 and total score over 3).
- You cannot have had a seizure in the past or be allergic to fampridine.
- You cannot have serious heart, kidney, or liver problems that could make side effects worse.
- You must not have taken fampridine or participated in another drug trial recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with spinocerebellar ataxia type 27B (a movement disorder) and their family members to understand how the condition changes over time. It also includes healthy volunteers for comparison.
This study tests an investigational drug given as a daily injection to see if it can improve walking and balance in people with Friedreich's ataxia.
This trial tests a rehabilitation program designed to help people with ataxia (a condition affecting coordination and balance) improve their walking and daily function. It aims to see if the program can help you move more safely and independently.
This study tests a brain pacemaker (called deep brain stimulation) placed in the cerebellum to help improve balance and coordination in people with SCA1 or SCA3. It aims to see if this treatment can reduce ataxia symptoms and improve daily function.
This study follows people with certain types of spinocerebellar ataxia (a group of conditions that cause progressive movement problems) to understand how the disease changes over time and how genes might influence it. It may help researchers learn more about these conditions and support future treatments.
This study tests whether a non-invasive brain stimulation treatment (called cerebellar transcranial magnetic stimulation) can help improve balance and coordination in people with spinocerebellar ataxia. It may offer a new way to ease symptoms without surgery.
Hear when a new Spinocerebellar Ataxia 27B (SCA27B) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.